Sam Brusco, Associate Editor08.17.22
Thermo Fisher Scientific has gained U.S. Food and Drug Administration (FDA) clearance for its ImmunoCAP Specific IgE (sIgE) Allergen Components test for wheat and sesame allergies. The diagnostic aid blood tests will soon be available nationwide.
ImmunoCAP Specific IgE Allergen Component Ses i 1 offers quantitative measurement of sIgE antibodies through a blood draw to help improve sesame seed allergy diagnosis. According to the company, the test provides higher specificity than skin prick testing extracts and whole allergen, in-vitro sIgE sesame tests.
“Sesame was recently added to the top nine major food allergen list through the FASTER ACT because sesame reactions are often dangerous and unpredictable,” Rebecca Rosenberger, MMSc, PA-C, Allergy Diagnostic & Treatment Center and associate director, Clinical Affairs & Education at Thermo Fisher Scientific, told the press. “Sesame is often a hidden allergen making the danger of accidental intake even greater. ImmunoCAP Specific IgE Allergen Component for sesame provides clinicians with a more complete assessment of the patient’s allergy. It also helps evaluate the risks associated with a severe systemic reaction (e.g., anaphylaxis) and to better qualify patients for an oral food challenge.”
ImmunoCAP Specific IgE Allergen Components for wheat measures IgE antibodies to Tri a 14 and Tri a 19 (omega-5-gliadin) components associated with severe reactions. Results help confirm IgE-mediated wheat allergy as a cause of symptoms, help identify clinically irrelevant sensitizations due to grass cross-reactivity, and improve avoidance recommendations.
“Wheat is the third most common food allergy, but it’s often misdiagnosed and confused with other digestive disorders like gluten intolerance and celiac disease,” said Rosenberger. “ImmunoCAP Specific IgE Allergen Components for wheat help clinicians pinpoint true allergies and distinguish between wheat sensitization and grass cross-reactivity. This can prevent unnecessary diet restrictions for many patients.”
ImmunoCAP Specific IgE Allergen Component Ses i 1 offers quantitative measurement of sIgE antibodies through a blood draw to help improve sesame seed allergy diagnosis. According to the company, the test provides higher specificity than skin prick testing extracts and whole allergen, in-vitro sIgE sesame tests.
“Sesame was recently added to the top nine major food allergen list through the FASTER ACT because sesame reactions are often dangerous and unpredictable,” Rebecca Rosenberger, MMSc, PA-C, Allergy Diagnostic & Treatment Center and associate director, Clinical Affairs & Education at Thermo Fisher Scientific, told the press. “Sesame is often a hidden allergen making the danger of accidental intake even greater. ImmunoCAP Specific IgE Allergen Component for sesame provides clinicians with a more complete assessment of the patient’s allergy. It also helps evaluate the risks associated with a severe systemic reaction (e.g., anaphylaxis) and to better qualify patients for an oral food challenge.”
ImmunoCAP Specific IgE Allergen Components for wheat measures IgE antibodies to Tri a 14 and Tri a 19 (omega-5-gliadin) components associated with severe reactions. Results help confirm IgE-mediated wheat allergy as a cause of symptoms, help identify clinically irrelevant sensitizations due to grass cross-reactivity, and improve avoidance recommendations.
“Wheat is the third most common food allergy, but it’s often misdiagnosed and confused with other digestive disorders like gluten intolerance and celiac disease,” said Rosenberger. “ImmunoCAP Specific IgE Allergen Components for wheat help clinicians pinpoint true allergies and distinguish between wheat sensitization and grass cross-reactivity. This can prevent unnecessary diet restrictions for many patients.”